Clinical Trial Update: Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer [Phase 3]

View source ↗

Summary

This update notes a Phase 3 trial evaluating relacorilant in combination with nab-paclitaxel for advanced platinum-resistant ovarian, primary peritoneal, or fal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Relacorilant (relacorilant)

Snippet

Sponsor: Corcept Therapeutics | Conditions: Ovarian Neoplasm, Fallopian Tube Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING